“sarepta-therapeutics” Archives

in
Entry Author Date Location
After a Clinical Trial Death, FDA OKs New Tests of Akashi’s Duchenne Drug 03/22/17 Boston
For $140M, PTC Gets Duchenne Drug and a Pricing Controversy from Marathon 03/16/17 New York
Nonprofit Seeds Exonics to Fund Push For CRISPR Duchenne Treatment 02/27/17 Boston
Bio Roundup: Trump Backlash, Verdine Plans, Sarepta Sale & More 02/24/17 National
Cashing in On Duchenne Approval, Sarepta Sells Voucher to Gilead For $125M 02/21/17 Boston
His Gene Therapy Near Approval, Spark CEO Wonders: What Price Vision? 02/16/17 New York
Anthem Caps Coverage Of Biogen Spine Drug Despite Wide FDA Approval 01/24/17 Boston
Biotech Roundup: JPM Deals, Gender Diversity, PCSK9 Battle & More 01/13/17 National
Notes From The JPM ’17 Vortex: Trump, Rainstorms & The Price You Pay 01/13/17 National
CEO Kaye Details Insurance Battle As Sarepta Launches Duchenne Drug 01/10/17 Boston
Families Fret As Insurers Mull Biogen’s $750K Spine Disease Drug 01/06/17 National
Biogen Sets $750,000 Initial Price For First-Ever Spinal Atrophy Drug 12/28/16 Boston
Top Stories of 2016 for Xconomy Boston: Editor’s Picks 12/26/16 Boston
Senate Approves 21st Century Cures Act, Sending Bill to Obama 12/07/16 National
Bio Roundup: Drug Pricing, Cystic Fibrosis Showdown, Myovant & More 10/28/16 National
Bio Roundup: Jenkins Gets Mad, Bernie Gets His Pen, CRISPR IPO & J-Lo 10/21/16 National
Defying Patient Pressure, Anthem Says No to Sarepta’s Duchenne Drug 10/07/16 Boston
Exact Sciences, Rockwell, & Gender Gaps: This Week’s WI Watchlist 10/04/16 Wisconsin
Post FDA Approval, Sarepta Wheels and Deals for Combo Duchenne Drugs 10/04/16 Boston
Bio Roundup: CAR-T & Migraine Races, Intra-Cellular, Rockefeller & More 09/30/16 National
Bio Execs Talk Patient Advocacy, Duchenne Approval at BioForward Panel 09/28/16 Wisconsin
Sarepta Preps For Sales As Insurers Unlikely To Deny Duchenne Drug 09/22/16 Boston
Sarepta Prices $300K Duchenne Drug As FDA Rift Emerges Over Approval 09/19/16 Boston
After New Data, FDA Bucks Advisory Panel, Approves Sarepta’s Duchenne Drug 09/19/16 Boston
Biotech Roundup: CRISPR’s 3rd IPO, Gender Diversity, Buyouts & More 09/16/16 National
Bio Roundup: Mylan’s Shock, Hillary’s 3%, Duchenne Lessons & More 08/26/16 National
Duchenne Lessons: Advocates For Rare Spinal Disease Have Eyes on FDA 08/26/16 National
Sarepta Stock Down as FDA Seeks More Data from Rival Duchenne Drug 07/14/16 Boston
Biotech Roundup: ASCO, BIO, Drug Setbacks, Incubators & More 06/10/16 National
Biotech Roundup: Deals Gone Wrong, Ethical Red Flags & Bay Goodbyes 06/03/16 National
Page 1 of 4 next page »